Drug Search Results
More Filters [+]

COMP-02

Alternative Names: comp-02, comp02, comp 02
Latest Update: 2016-02-22
Latest Update Note: Clinical Trial Update

Product Description

Promius Pharma is developing COMP-02 as a treatment for Actinic Keratosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02126670)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Promius Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for COMP-02

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title